TachoSil
| Combination of | |
|---|---|
| Fibrinogen | Glycoprotein |
| Thrombin | Coagulation factor |
| Clinical data | |
| Trade names | Tachosil |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | Epilesional |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Tachosil is an equine collagen sponge coated with the human plasma-derived coagulation factors fibrinogen and thrombin.[2][5] It is used during surgery to stop local bleeding on internal organs (hemostasis).[2] Tachosil reacts upon contact with blood, other body fluids or saline to form a clot that glues it to the tissue surface.[4]
Tachosil may cause an allergic reaction, thrombosis (blood clots), a blockage in the intestine when used during abdominal surgeries, the formation of scar tissue and foreign body granuloma (a type of inflammatory reaction).[4]
Medical uses[edit]
Tachosil is indicated in for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient.[4] According to studies comparing Tachosil to argon beamer or stitching in patients undergoing liver surgery, Tachosil was associated with significantly lower time until the bleeding stopped.[1] Tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery.[4]
References[edit]
- ^ "TachoSil sealant matrix - Summary of Product Characteristics (SmPC)". (emc). 31 January 2020. Archived from the original on 10 July 2020. Retrieved 9 July 2020.
- ^ a b c "Tachosil- thrombin human and fibrinogen patch". DailyMed. 16 February 2023. Archived from the original on 19 May 2023. Retrieved 19 May 2023.
- ^ "Tachosil- thrombin human and fibrinogen patch". DailyMed. 2 November 2022. Archived from the original on 19 May 2023. Retrieved 19 May 2023.
- ^ a b c d e "TachoSil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 13 July 2020. Retrieved 9 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, et al. (2014). "Economic and outcomes consequences of Tachosil: a systematic review". Vascular Health and Risk Management. 10: 569–75. doi:10.2147/VHRM.S63199. PMC 4166367. PMID 25246797.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |